Comparing effects of a long acting GLP-1 receptor agonist liraglutide with a short acting GLP-1 receptor agonist lixisenatide on diabetic cardiac autonomic neuropathy and glycemic variability evaluated by power spectral analysis of 24-hr heart rate and continuous glucose monitoring.

Trial Profile

Comparing effects of a long acting GLP-1 receptor agonist liraglutide with a short acting GLP-1 receptor agonist lixisenatide on diabetic cardiac autonomic neuropathy and glycemic variability evaluated by power spectral analysis of 24-hr heart rate and continuous glucose monitoring.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Liraglutide (Primary) ; Lixisenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ELABORATE
  • Most Recent Events

    • 07 Jul 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 05 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top